Teva launches generic Delzicol
Teva is introducing a generic version of Allergan’s Delzicol (mesalamine) delayed-release capsules in a 400 mg dosage strength.
Mesalamine delayed-release capsules are an aminosalicylate indicated for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older and for the maintenance of remission of ulcerative colitis in adults.
“Ulcerative colitis is a chronic inflammatory bowel disease and we’re proud to provide another treatment option for patients,” Teva's executive vice president and head of North America Commercial, Brendan O’Grady said.
Delzicol delayed-release capsules have a market value of roughly $130 million, according to February 2019 IQVIA data.
Mesalamine delayed-release capsules are an aminosalicylate indicated for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older and for the maintenance of remission of ulcerative colitis in adults.
“Ulcerative colitis is a chronic inflammatory bowel disease and we’re proud to provide another treatment option for patients,” Teva's executive vice president and head of North America Commercial, Brendan O’Grady said.
Delzicol delayed-release capsules have a market value of roughly $130 million, according to February 2019 IQVIA data.